Becton, Dickinson and Company
One Becton Drive
552 articles with Becton, Dickinson and Company
The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.
BD, Helmer Scientific Collaborate to Introduce First Fully Integrated Refrigerated Automated Dispensing Solution
BD (Becton, Dickinson and Company) and Helmer Scientific announced a collaboration to introduce an industry-first, medical-grade refrigerated solution integrated with an automated dispensing system to provide clinicians secure, single line-item access to high-risk and high-value refrigerated medications.
BD (Becton, Dickinson and Company) announced that it will present at the several upcoming investor healthcare conferences.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer.
BD (Becton, Dickinson and Company) reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.
BD Launches BD FACSymphony™ High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types
BD (Becton, Dickinson and Company) announced the launch of the BD FACSymphony™ system, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell.
BD announced three executive appointments to the positions of segment president.
New Cell Sorter Extends BD's Robust Portfolio of Flow Cytometry Research Solutions
BD Synapsys™ Microbiology Informatics Solution Among New Offerings Shown at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Statement from FDA's Donald St. Pierre on findings from ongoing investigation into lead testing issues
BD studies find chemical interaction during test processing may contribute to skewing results
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it is updating the instructions for use of certain BD Vacutainer® tubes as part of its quality process to ensure that customers understand the appropriate uses of these products.
Funds advised by Apax Partners ("the Apax Funds") today announced they have entered into a definitive agreement to purchase from BD (Becton, Dickinson and Company) its remaining ownership interest in Vyaire Medical, Inc., a global leader in respiratory care.
BD (Becton, Dickinson and Company) announced the results of its previously announced offer to repurchase any and all of its outstanding 3.000% Notes due May 15, 2026 in accordance with the terms and conditions set forth in the offer to repurchase, dated January 8, 2018.
The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD's acquisition of C. R. Bard which was completed on Dec. 29, 2017.
BD Announces Results for 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated for Inclusion of Bard
BD today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31, 2017.
The indicated annual dividend rate is $3.00 per share.
BD today announced the completion of enrollment in the Lutonix BTK trial and plans to submit a pre-market approval application in late 2018.
BD announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2018, at 1 p.m.
The new test provides diagnostic results up to 10 times faster than traditional tests.
These violations were discovered through an inspection of BD's New Jersey facility.